33
Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech’s cash is running out and it may have to file for bankruptcy protection.
Shares in the South San Francisco-based company – already into penny share territory since Quince revealed last month that its lead drug for genetic disorder ataxia-telangiectasia (A-T) had failed a phase 3 trial – lost two-thirds of their value after the announcement.
In an update to the Securities & Exchange Commission (SEC) in the US, Quince said it ended 2025 with less than $6 million in cash, around $12…